Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 13/20 | 0.63 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | JAK3 | P52333 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.49 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7021941 | 0.94 | LCK (0.64) | LCKJAK2JAK3NPC1RAB9A | |
| SCHEMBL7024895 | 0.89 | LCK (0.68) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7017981 | 0.87 | LCK (0.71) | LCKJAK2JAK3NPC1RAB9A | |
| SCHEMBL7022622 | 0.84 | JAK2 (0.63) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7018143 | 0.84 | LCK (0.68) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7662698 | 0.84 | LCK (0.68) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7014887 | 0.83 | LCK (0.69) | LCKJAK2JAK3NPC1RAB9A | |
| SCHEMBL7016999 | 0.82 | LCK (0.63) | LCKJAK2JAK3ALDH1A1MKNK1 | |
| SCHEMBL7024707 | 0.82 | LCK (0.71) | LCKJAK2JAK3NPC1RAB9A | |
| SCHEMBL7021308 | 0.81 | LCK (0.65) | LCKJAK2JAK3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1206265-B1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2003-11-12 | — | — | EP | disclosed |
| US-6498165-B1 | PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS | MERCK & CO., INC. | 2002-12-24 | — | — | US | disclosed |